Eli Lilly, Low Risk Stocks

Is Eli Lilly and Company (LLY) the Best Low Risk Stock to Buy In 2025?
We recently compiled a list of the 10 Best Low Risk Stocks To Buy in 2025. In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against the other low risk stocks.
Is Eli Lilly Stock a Buy?
Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer. The Motley Fool reaches millions of people every month through our premium investing solutions, free guidance and market analysis on Fool.com, top-rated podcasts, and non-profit The Motley Fool Foundation.
Eli Lilly & Co. stock underperforms Friday when compared to competitors
Shares of Eli Lilly & Co. LLY slid 4.73% to $869.58 Friday, on what proved to be an all-around positive trading session for the stock market, with the S&P 500 Index SPX rising 0.55% to 5,770.20 and the Dow Jones Industrial Average DJIA rising 0.52% to 42,801.72.
Eli Lilly Rises 7.5% YTD: Time to Buy, Sell or Hold the Stock?
Eli Lilly and Company’s LLY shares dipped almost 5% on Monday after rival Novo Nordisk NVO announced disappointing data from a late-stage study on next-generation obesity drug, CagriSema. Top-line data from the phase III REDEFINE 2 study on Novo Nordisk’s CagriSema showed that treatment with the drug led to a weight loss of 15.
Why Eli Lilly Stock Flopped Today
Zeroing in on Eli Lilly, the company is already well established with Zepbound, which should continue to sell briskly as the world waits for a more powerful and efficacious obesity drug to hit the market. Besides, the American pharmaceutical king has many other products currently on pharmacy shelves, and a wide and active pipeline.
Here’s Why Eli Lilly and Company (LLY) has Come Under Pressure
Polen Capital, an investment management company, released its “Polen Focus Growth Strategy” fourth quarter 2024 investor ...
Indianapolis Star on MSN13d
Eli Lilly will build 4 new manufacturing sites to increase domestic drug production
Eli Lilly and Co. is in negotiations with several states and plans to announce the locations of four new manufacturing plants ...
STAT12h
Eli Lilly’s Dave Ricks takes home $114 million as obesity drugs fuel company’s fortunes
Eli Lilly’s rising fortunes tied to its weight loss and diabetes drugs led to a nine-figure payday for its top executive.
Eli Lilly plans to launch weight-loss drug in emerging markets this year
Eli Lilly plans to launch Mounjaro, its blockbuster diabetes drug, in countries like China, India, Brazil and Mexico by 2026, ...
Eli Lilly plans to invest $27B to build four new US plants as tariffs loom
Pharmaceutical giant expects the move will create 3,000 high-skilled jobs and provide work for approximately 10,000 ...
CNN on MSN13d
Zepbound maker Eli Lilly announces $27 billion investment in US drug manufacturing as Trump threatens tariffs
David Ricks, Eli Lilly’s chief executive officer, told CNN that the company – whose revenue grew 32% to $45 billion ...
Fierce Pharma1d
With Eli Lilly flying high, CEO David Ricks collects 10% pay bump to $29.2M
Presiding over the upward trajectory of Eli Lilly over the last eight years is paying off nicely for CEO David Ricks. | ...
Yahoo Finance4d
Eli Lilly and Company (LLY): Among The Stocks With At Least $10 Million In Insider Sales Recently
In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against the other stocks. Some of the major U.S. indexes began recovering on Wednesday, following ...
Novo Nordisk Stock Drops on New Obesity Drug Findings. Eli Lilly Stands to Gain.
The Danish company said the average weight loss was 15.7% for the new drug, CagriSema. The expectation had been about 25%.